This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal

Arch Ophthalmol. 1999;117:673-674.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

IN THIS issue of the ARCHIVES, Maus et al¹ demonstrate and quantify the effects of single doses of the ₂-adrenergic agonists brimonidine tartrate and apraclonidine hydrochloride and the prostaglandin receptor agonist latanoprost on intraocular pressure (IOP) and aqueous humor flow (AHF) in timolol-treated human eyes. The authors interpret their data as indicating that all 3 drugs further reduce "timolol-treated" IOP to a similar extent, apraclonidine and brimonidine doing so essentially exclusively by further suppressing AHF with no effect on aqueous outflow, latanoprost doing so essentially exclusively by enhancing aqueous outflow (presumably uveoscleral) with no effect on AHF. Furthermore, they found the magnitude of the AHF-suppressing effects of apraclonidine and brimonidine to be essentially identical. These data and their interpretation highlight several areas of interest and uncertainty in the clinical physiology of AHF dynamics and glaucoma therapy.

Apraclonidine and brimonidine each reduced AHF by approximately 0.25 µL/min, 20%, from the timolol-treated . . . [Full Text of this Article]

RELATED ARTICLE

Comparison of the Early Effects of Brimonidine and Apraclonidine as Topical Ocular Hypotensive Agents
Todd L. Maus, Cherie Nau, and Richard F. Brubaker
Arch Ophthalmol. 1999;117(5):586-591.
ABSTRACT | FULL TEXT